Sandlund John T, Guillerman R Paul, Perkins Sherrie L, Pinkerton C Ross, Rosolen Angelo, Patte Catherine, Reiter Alfred, Cairo Mitchell S
John T. Sandlund, St Jude Children's Research Hospital, Memphis, TN; R. Paul Guillerman, Texas Children's Hospital, Houston, TX; Sherrie L. Perkins, University of Utah Health Sciences Center, Salt Lake City, UT; C. Ross Pinkerton, University of Queensland, Brisbane, Queensland, Australia; Angelo Rosolen, University of Padova, Padova, Italy; Catherine Patte, Institut Gustave Roussy, Paris, France; Alfred Reiter, Justus-Liebig-University of Giessen, Giessen, Germany; and Mitchell S. Cairo, New York Medical College, Valhalla, NY.
J Clin Oncol. 2015 Jun 20;33(18):2106-11. doi: 10.1200/JCO.2014.59.0745. Epub 2015 May 4.
Response criteria are well established for adult patients with non-Hodgkin lymphoma (NHL). A revised set of response criteria in adults with NHL was recently published. However, NHL in children and adolescents involves different histologies, primary sites of disease, patterns of metastatic spread, approaches to therapy, and responses to treatment compared with adult NHL. However, there are no standardized response criteria specific to pediatric NHL. Therefore, we developed international standardized methods for assessing response to therapy in children and adolescents with NHL.
An international multidisciplinary group of pediatric oncologists, pathologists, biologists, and radiologists convened during and after the Third and Fourth International Childhood, Adolescent and Young Adult NHL Symposia to review existing response and outcome data, develop methods for response evaluation that reflect incorporation of more sensitive technologies currently in use, and incorporate primary and metastatic sites of disease for the evaluation of therapeutic response in children and adolescents with NHL.
Using the current adult NHL response criteria as a starting point, international pediatric NHL response criteria were developed incorporating both contemporary diagnostic imaging and pathology techniques, including novel molecular and flow cytometric technologies used for the determination of minimal residual disease.
Use of the international pediatric NHL response criteria in children and adolescents receiving therapy for NHL incorporates data obtained from new and more sensitive technologies that are now being widely used for disease evaluation, providing a standardized means for reporting treatment response.
针对成年非霍奇金淋巴瘤（NHL）患者的疗效评估标准已确立。最近发布了一套修订后的成年NHL疗效评估标准。然而，与成年NHL相比，儿童和青少年NHL涉及不同的组织学类型、疾病原发部位、转移扩散模式、治疗方法及治疗反应。然而，尚无专门针对儿童NHL的标准化疗效评估标准。因此，我们制定了评估儿童和青少年NHL治疗反应的国际标准化方法。
一个由儿科肿瘤学家、病理学家、生物学家和放射学家组成的国际多学科小组在第三届和第四届国际儿童、青少年及青年成人NHL研讨会期间及会后召开会议，回顾现有的疗效和预后数据，制定疗效评估方法，以反映当前正在使用的更敏感技术的纳入情况，并纳入疾病的原发和转移部位，用于评估儿童和青少年NHL的治疗反应。
以当前成年NHL疗效评估标准为起点，制定了国际儿童NHL疗效评估标准，纳入了当代诊断成像和病理学技术，包括用于确定微小残留病的新型分子和流式细胞术技术。
在接受NHL治疗的儿童和青少年中使用国际儿童NHL疗效评估标准，纳入了从现在广泛用于疾病评估的新的和更敏感技术中获得的数据，为报告治疗反应提供了标准化手段。
